Cargando…

Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option

INTRODUCTION: According to the Global Initiative for chronic obstructive lung disease (GOLD), when a treatment is not achieving an appropriate response it should be switched taking into account the predominant treatable trait to target (dyspnea or exacerbations). The objective of the present study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Soler-Cataluña, Juan José, Huerta, Arturo, Almagro, Pere, González-Segura, Diego, Cosío, Borja G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332360/
https://www.ncbi.nlm.nih.gov/pubmed/37434953
http://dx.doi.org/10.2147/COPD.S414910
_version_ 1785070424950833152
author Soler-Cataluña, Juan José
Huerta, Arturo
Almagro, Pere
González-Segura, Diego
Cosío, Borja G
author_facet Soler-Cataluña, Juan José
Huerta, Arturo
Almagro, Pere
González-Segura, Diego
Cosío, Borja G
author_sort Soler-Cataluña, Juan José
collection PubMed
description INTRODUCTION: According to the Global Initiative for chronic obstructive lung disease (GOLD), when a treatment is not achieving an appropriate response it should be switched taking into account the predominant treatable trait to target (dyspnea or exacerbations). The objective of the present study was to investigate the lack of clinical control according to the target and medication groups. MATERIALS AND METHODS: This was a post-hoc analysis of the CLAVE study, an observational, cross-sectional, multicenter study which evaluated the clinical control, and related-factors, in a cohort of 4801 patients with severe chronic obstructive pulmonary disease (COPD). The primary endpoint was the percentage of uncontrolled patients defined as COPD Assessment Test (CAT) >16 or presence of exacerbations in the last 3 months despite receiving long-acting beta(2)-agonist (LABA) and/or long-acting antimuscarinic antagonist (LAMA) with or without inhaled corticosteroids (ICS). Secondary objectives included the description of sociodemographic and clinical characteristics of patients by therapeutic group and the identification of characteristics potentially associated with the lack of control of COPD including low adherence measured by the test to adherence to inhalers (TAI). RESULTS: In the dyspnea pathway, lack of clinical control was of 25.0% of patients receiving LABA or LAMA in monotherapy, 29.5% by those with LABA + LAMA, 38.3% with LABA + ICS and 37.0% with triple therapy (LABA + LAMA + ICS). In the exacerbation pathway, percentages were 87.1%, 76.7%, 83.3%, and 84.1%, respectively. Low physical activity and high Charlson comorbidity index were independent factor of non-control in all therapeutic groups. Additional factors were lower post-bronchodilator FEV1 and poor adherence to inhalers. CONCLUSION: There are still room for improvement in COPD control. From the pharmacological perspective, every step in treatment have a pool of uncontrolled patients in which a step-up could be considered according to a trait to target strategy.
format Online
Article
Text
id pubmed-10332360
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103323602023-07-11 Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option Soler-Cataluña, Juan José Huerta, Arturo Almagro, Pere González-Segura, Diego Cosío, Borja G Int J Chron Obstruct Pulmon Dis Original Research INTRODUCTION: According to the Global Initiative for chronic obstructive lung disease (GOLD), when a treatment is not achieving an appropriate response it should be switched taking into account the predominant treatable trait to target (dyspnea or exacerbations). The objective of the present study was to investigate the lack of clinical control according to the target and medication groups. MATERIALS AND METHODS: This was a post-hoc analysis of the CLAVE study, an observational, cross-sectional, multicenter study which evaluated the clinical control, and related-factors, in a cohort of 4801 patients with severe chronic obstructive pulmonary disease (COPD). The primary endpoint was the percentage of uncontrolled patients defined as COPD Assessment Test (CAT) >16 or presence of exacerbations in the last 3 months despite receiving long-acting beta(2)-agonist (LABA) and/or long-acting antimuscarinic antagonist (LAMA) with or without inhaled corticosteroids (ICS). Secondary objectives included the description of sociodemographic and clinical characteristics of patients by therapeutic group and the identification of characteristics potentially associated with the lack of control of COPD including low adherence measured by the test to adherence to inhalers (TAI). RESULTS: In the dyspnea pathway, lack of clinical control was of 25.0% of patients receiving LABA or LAMA in monotherapy, 29.5% by those with LABA + LAMA, 38.3% with LABA + ICS and 37.0% with triple therapy (LABA + LAMA + ICS). In the exacerbation pathway, percentages were 87.1%, 76.7%, 83.3%, and 84.1%, respectively. Low physical activity and high Charlson comorbidity index were independent factor of non-control in all therapeutic groups. Additional factors were lower post-bronchodilator FEV1 and poor adherence to inhalers. CONCLUSION: There are still room for improvement in COPD control. From the pharmacological perspective, every step in treatment have a pool of uncontrolled patients in which a step-up could be considered according to a trait to target strategy. Dove 2023-07-06 /pmc/articles/PMC10332360/ /pubmed/37434953 http://dx.doi.org/10.2147/COPD.S414910 Text en © 2023 Soler-Cataluña et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Soler-Cataluña, Juan José
Huerta, Arturo
Almagro, Pere
González-Segura, Diego
Cosío, Borja G
Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
title Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
title_full Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
title_fullStr Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
title_full_unstemmed Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
title_short Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
title_sort lack of clinical control in copd patients depending on the target and the therapeutic option
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332360/
https://www.ncbi.nlm.nih.gov/pubmed/37434953
http://dx.doi.org/10.2147/COPD.S414910
work_keys_str_mv AT solercatalunajuanjose lackofclinicalcontrolincopdpatientsdependingonthetargetandthetherapeuticoption
AT huertaarturo lackofclinicalcontrolincopdpatientsdependingonthetargetandthetherapeuticoption
AT almagropere lackofclinicalcontrolincopdpatientsdependingonthetargetandthetherapeuticoption
AT gonzalezseguradiego lackofclinicalcontrolincopdpatientsdependingonthetargetandthetherapeuticoption
AT cosioborjag lackofclinicalcontrolincopdpatientsdependingonthetargetandthetherapeuticoption
AT lackofclinicalcontrolincopdpatientsdependingonthetargetandthetherapeuticoption